By: Nathesh “Relay Technology Management (Relay TM) will be making use of the TIBCO Spotfire analytics platform to run Business Development Live (BD Live!), its real-time business intelligence and data visualization solution for life science professionals and also power.” Read full article.
By John Carroll Shares of Parexel International took a beating this morning after the CRO noted a shortfall in early-phase research work that is triggering a restructuring in that segment of its drug research business. Parexel, one of the top CROs in the business, also cut its outlook on 2011. And investors responded by taking …
By John Carroll While Wall Street has been transfixed by signs that Pfizer CEO Ian Read is preparing to sell off large chunks of its business so it can concentrate on pharmaceutical sales and new drug development to replace the blockbusters slated to lose patent protection, Read has been pushing full-steam-ahead on plans to radically …
By John Carroll Say goodbye to AstraZeneca’s decade-old research hub in Delaware. Defying local economic development officials, the pharma company–which is undergoing a top-to-bottom restructuring of its global development efforts–plans to demolish 450,000 square feet of space at its North American headquarters. The three buildings marked for destruction, part of a sprawling campus in Fairfax, …
By John Carroll With Pfizer ($PFE) pushing a top-to-bottom restructuring on the R&D side as it carves billions of dollars from its R&D budget, analysts at Jefferies & Co. say that the pharma giant will soon whittle down its list of vendors, helping drive a broad consolidation of the CRO field as Big Pharma lines up …
By Maureen Martino Want proof that achieving FDA approval is more difficult than in the past? A study released by the BIO and BioMedTracker that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previously the rate of approval were one …
By Stewart Lyman Cognitive dissonance is defined as “an uncomfortable feeling caused by holding conflicting ideas simultaneously.” I’m suffering from a serious case of discomfort as I try to figure out which is the bigger problem facing biotech scientists: too much information, or too little. Information overload is a serious issue in biomedical research, if not …
By John Carroll Sanofi-Aventis’ GLP-1 diabetes drug lixisenatide impressed analysts with a solid set of top-line results demonstrating its effectiveness–in combination with the bestselling Lantus–for controlling blood sugar. Adding a daily injection of lixisenatide helped Type 2 diabetes patients who had trouble controlling the disease with basal insulin alone. Analysts at Bryan, Garnier has already …
By John Carroll Cambridge, MA-based Acceleron has inked a $498 million development deal with Shire covering the ex-U.S. rights to its closely watched lead therapy, ACE-031. Shire is paying $45 million upfront and committing itself to up to $453 million more in a slate of milestones to snag the international marketing rights to the therapy–as …
By John Carroll In a bid to break out of its dependence on manufacturing and cheap labor, the Chinese government is planning to invest $1.5 billion into new drug development between 2011 and 2016. And biotechnology is one of seven emerging industries that the Asian powerhouse will use to spearhead the next big step in …
